Seven Fleet Capital Management LP Acquires Shares of 284,430 Damora Therapeutics, Inc. Common Stock $DMRA

Seven Fleet Capital Management LP bought a new position in Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in the second quarter, HoldingsChannel reports. The firm bought 284,430 shares of the company’s stock, valued at approximately $7,398,000. Damora Therapeutics, Inc. Common Stock accounts for 1.2% of Seven Fleet Capital Management LP’s holdings, making the stock its 18th largest holding.

Other large investors have also recently modified their holdings of the company. Janus Henderson Group PLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $40,000. Virtu Financial LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the third quarter worth $49,000. Two Sigma Investments LP purchased a new position in Damora Therapeutics, Inc. Common Stock during the third quarter worth $76,000. Connective Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the third quarter valued at $100,000. Finally, Geode Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $266,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Stock Up 7.4%

DMRA stock opened at $30.06 on Friday. The business’s fifty day simple moving average is $29.74 and its two-hundred day simple moving average is $26.89. Damora Therapeutics, Inc. Common Stock has a twelve month low of $2.45 and a twelve month high of $38.33. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -8.92 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. Research analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on DMRA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 18th. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Jefferies Financial Group started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 price objective for the company. Finally, Wedbush boosted their target price on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, July 30th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $44.00.

Damora Therapeutics, Inc. Common Stock Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.